HomeCompareCNCE vs O

CNCE vs O: Dividend Comparison 2026

CNCE yields 23.89% · O yields 5.28%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 CNCE wins by $58.2K in total portfolio value
10 years
CNCE
CNCE
● Live price
23.89%
Share price
$8.37
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$92.5K
Annual income
$10,014.51
Full CNCE calculator →
O
Realty Income Corporation
● Live price
5.28%
Share price
$61.15
Annual div
$3.23
5Y div CAGR
15.1%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$34.2K
Annual income
$5,102.74
Full O calculator →

Portfolio growth — CNCE vs O

📍 CNCE pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodCNCEO
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, CNCE + O cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
CNCE pays
O pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

CNCE
Annual income on $10K today (after 15% tax)
$2,031.06/yr
After 10yr DRIP, annual income (after tax)
$8,512.33/yr
O
Annual income on $10K today (after 15% tax)
$449.12/yr
After 10yr DRIP, annual income (after tax)
$4,337.33/yr
At 15% tax rate, CNCE beats the other by $4,175.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of CNCE + O for your $10,000?

CNCE: 50%O: 50%
100% O50/50100% CNCE
Portfolio after 10yr
$63.3K
Annual income
$7,558.63/yr
Blended yield
11.93%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on CNCE right now

CNCE
Analyst Ratings
16
Buy
1
Hold
Consensus: Buy
Altman Z
2.4
Piotroski
1/9
O
Analyst Ratings
13
Buy
18
Hold
3
Sell
Consensus: Hold
Price Target
$64.00
+4.7% upside vs current
Range: $60.00 — $69.00
Altman Z
1.0
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

CNCE buys
0
O buys
0
No recent congressional trades found for CNCE or O in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricCNCEO
Forward yield23.89%5.28%
Annual dividend / share$2.00$3.23
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%15.1%
Portfolio after 10y$92.5K$34.2K
Annual income after 10y$10,014.51$5,102.74
Total dividends collected$57.3K$20.7K
Payment frequencyquarterlymonthly
SectorStockREIT
Analyst consensusBuyHold

Year-by-year: CNCE vs O ($10,000, DRIP)

YearCNCE PortfolioCNCE Income/yrO PortfolioO Income/yrGap
1← crossover$13,089$2,389.49$10,818$608.16+$2.3KCNCE
2$16,929$2,923.10$11,787$741.68+$5.1KCNCE
3$21,647$3,533.17$12,946$911.00+$8.7KCNCE
4$27,385$4,222.32$14,345$1,127.94+$13.0KCNCE
5$34,294$4,992.02$16,056$1,409.05+$18.2KCNCE
6$42,537$5,842.50$18,171$1,777.83+$24.4KCNCE
7$52,287$6,772.75$20,820$2,268.21+$31.5KCNCE
8$63,728$7,780.57$24,188$2,929.90+$39.5KCNCE
9$77,051$8,862.62$28,533$3,837.11+$48.5KCNCE
10$92,459$10,014.51$34,235$5,102.74+$58.2KCNCE

CNCE vs O: Complete Analysis 2026

CNCEStock

Concert Pharmaceuticals, Inc. operates as a clinical stage biopharmaceutical company that develops novel small molecule drugs for the treatment of autoimmune diseases. The company's lead product candidate is CTP-543, which is in Phase III clinical trial for the treatment of alopecia areata, a serious autoimmune dermatological condition. It has strategic collaborations with Avanir Pharmaceuticals, Inc.; Jazz Pharmaceuticals, Inc.; Cipla Technologies; and Processa Pharmaceuticals. The company was incorporated in 2006 and is headquartered in Lexington, Massachusetts.

Full CNCE Calculator →

OREIT

Realty Income, The Monthly Dividend Company, is an S&P 500 company dedicated to providing stockholders with dependable monthly income. The company is structured as a REIT, and its monthly dividends are supported by the cash flow from over 6,500 real estate properties owned under long-term lease agreements with our commercial clients. To date, the company has declared 608 consecutive common stock monthly dividends throughout its 52-year operating history and increased the dividend 109 times since Realty Income's public listing in 1994 (NYSE: O). The company is a member of the S&P 500 Dividend Aristocrats index. Additional information about the company can be obtained from the corporate website at www.realtyincome.com.

Full O Calculator →
📬

Get this CNCE vs O comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

CNCE vs SCHDCNCE vs JEPICNCE vs KOCNCE vs MAINCNCE vs STAGCNCE vs ADCCNCE vs NNNCNCE vs VICI

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.